Your browser doesn't support javascript.
loading
Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
Kwong, Ava; Ho, John C W; Shin, Vivian Y; Kurian, Allison W; Tai, Edmund; Esserman, Laura J; Weitzel, Jeffery N; Lin, Po-Han; Field, Michael; Domchek, Susan M; Lo, Jessica; Ngan, Hextan Y S; Ma, Edmond S K; Chan, Tsun L; Ford, James M.
Afiliación
  • Kwong A; Department of Surgery, The University of Hong Kong, Hong Kong, China.
  • Ho JCW; Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, China.
  • Shin VY; Department of Surgery, Hong Kong Sanatorium & Hospital, Hong Kong, China.
  • Kurian AW; Department of Surgery, The University of Hong Kong, Hong Kong, China.
  • Tai E; Department of Surgery, The University of Hong Kong, Hong Kong, China.
  • Esserman LJ; Department of Medicine, Health Research & Policy and Genetics, Stanford University School of Medicine, Stanford, CA, United States.
  • Weitzel JN; Palo Alto Medical Foundation, Palo Alto, CA, United States.
  • Lin PH; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, United States.
  • Field M; Division of Clinical Cancer Genomics, City of Hope, Duarte, CA, United States.
  • Domchek SM; Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.
  • Lo J; Department of Clinical Genetics, Royal North Shore Hospital, St Leonards, NSW, Australia.
  • Ngan HYS; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
  • Ma ESK; Department of Surgery, The University of Hong Kong, Hong Kong, China.
  • Chan TL; Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong, China.
  • Ford JM; Department of Molecular Pathology, Hong Kong Sanatorium & Hospital, Hong Kong, China.
Oncotarget ; 9(8): 7832-7843, 2018 Jan 30.
Article en En | MEDLINE | ID: mdl-29487695
BRCA1/2 mutations are significant risk factors for hereditary breast and ovarian cancer (HBOC), its mutation frequency in HBOC of Chinese ethnicity is around 9%, in which nearly half are recurrent mutations. In Hong Kong and China, genetic testing and counseling are not as common as in the West. To reduce the barrier of testing, a multiplex SNaPshot genotyping panel that targeted 25 Chinese BRCA1/2 mutation hotspots was developed, and its feasibility was evaluated in a local cohort of 441 breast and 155 ovarian cancer patients. For those who tested negative, they were then subjected to full-gene testing with next-generation sequencing (NGS). BRCA mutation prevalence in this cohort was 8.05% and the yield of the recurrent panel was 3.52%, identifying over 40% of the mutation carriers. Moreover, from 79 Chinese breast cancer cases recruited overseas, 2 recurrent mutations and one novel BRCA2 mutation were detected by the panel and NGS respectively. The developed genotyping panel showed to be an easy-to-perform and more affordable testing tool that can provide important contributions to improve the healthcare of Chinese women with cancer as well as family members that harbor high risk mutations for HBOC.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: China